Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

73.20 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26
Open 73.20
Bid (Size) 73.08 (13)
Ask (Size) 73.16 (22)
Prev. Close 73.20
Today's Range 73.20 - 73.20
52wk Range 52.65 - 76.56
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$100 Invested In AstraZeneca 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
AstraZeneca's Tagrisso Significantly Enhances Survival in Certain Post Surgery Non-Small Cell Lung Cancer Patients
 
Via Benzinga

Performance

YTD
+5.58%
+5.58%
1 Month
-2.83%
-2.83%
3 Month
+13.38%
+13.38%
6 Month
+6.99%
+6.99%
1 Year
+15.24%
+15.24%

More News

Read More
Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
From AstraZeneca
Via Business Wire
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,000 Today
Via Benzinga
ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care
From AstraZeneca
Via Business Wire
TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
From AstraZeneca
Via Business Wire
LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
3 Nasdaq 100 Stocks That Are Surefire Buys in June
Via The Motley Fool
LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
From AstraZeneca
Via Business Wire
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
Via Talk Markets
Nvidia Becomes Ninth Company To Hit $1 Trillion Market Cap — Who Could Be Next To Join Elusive Club?
Via Benzinga
Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years
Via The Motley Fool
Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today
Via Benzinga
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
From AstraZeneca
Via Business Wire
AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer
Via Benzinga
AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
From AstraZeneca
Via Business Wire
As Debt Ceiling Talks Wobble, Investors Look To May Fed Minutes, Nvidia Earnings For Direction
Via Benzinga
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter
Via Benzinga
New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD
From AstraZeneca
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal
Via Talk Markets
3 Undervalued Pharma Stocks to Buy for High Total Returns
Via InvestorPlace
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.